



30 July 2015

ASX ANNOUNCEMENT

APPENDIX 4C – QUARTER ENDED 30 JUNE 2015

Brisbane, Australia – **ImpediMed Limited** (ASX: IPD) (“The Company”) today released its Appendix 4C – Quarterly cash flow report for the period ended 30 June 2015.

Total revenue for the quarter was \$1.3 million, including lymphoedema sales of \$0.6 million. Operating cash outflow for the quarter was \$3.0 million. Cash receipts from customers for the quarter were \$1.5 million and cash on hand as of 30 June 2015 was \$32.6 million.

Highlights;

- Lymphoedema management being included in interim NCCN Guidelines[®] for Breast Cancer for the first time (final version released in July)
- Two additional premier US cancer centres joining the US Commercial L-Dex[®] pilot program
- University of Kansas Cancer Centre, a National Cancer Institute (NCI) designated comprehensive cancer centre, joining the L-Dex post approval clinical trial
- Richard Carreon joining the Board of Directors
- L-Dex being featured at key international conference – American Society of Breast Surgeons (ASBrS)
- L-Dex inventor, Professor Leigh Ward, receiving prestigious Clunies Ross award

“The experiences gathered from the commercial pilots to date provide a clear path forward for our full US commercial launch later this year. In addition, having lymphoedema included in the NCCN Guidelines[®] for Breast Cancer is an important step forward for the care of cancer survivors and significantly increases the opportunity to integrate L-Dex into large multidisciplinary centres”, stated Managing Director and CEO, Richard Carreon.

– ENDS –

Richard Carreon
Managing Director & CEO

For further information contact:
Richard Carreon, ImpediMed Managing Director & CEO
Morten Vigeland, ImpediMed CFO
T: +1 (760) 585-2100

Kyahn Williamson, Buchan
Investor and Media Relations

For personal use only

T: +61 3 9866 4722

E: kwilliamson@buchanwe.com.au

About ImpediMed

ImpediMed Limited is the world leader in the development and distribution of medical devices employing Bioimpedance Spectroscopy (BIS) technologies for use in the non-invasive clinical assessment and monitoring of fluid status. ImpediMed's primary product range consists of a number of medical devices that aid surgeons, oncologists, therapists and radiation oncologists in the clinical assessment of patients for the potential onset of secondary lymphoedema. Pre-operative clinical assessment in cancer survivors, before the onset of symptoms, may prevent the condition from becoming a lifelong management issue and thus improve the quality of life of the cancer survivor. ImpediMed has the first medical device with an FDA clearance in the United States to aid health care professionals, clinically assess secondary unilateral lymphoedema of the arm and leg in women and the leg in men.

For more information, visit: www.impedimed.com.au

For personal use only